Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers

NCT04188548 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04188548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04188548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 10, 2019
Completion date
December 31, 2027
Enrollment
379 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, endometrial cancer, metastatic breast cancer